Enter multiple symbols separated by commas

Alzheimer's Drug Could Save U.S. Trillions, New Study Says

A new study says if a drug is quickly developed that delays the onset of Alzheimer's Disease it would save the U.S. economy trillions of dollars.

The group, which goes by the acronym ACT-AD, claims this is the first economic estimate of the impact new drugs could have.

The results show that if an Alzheimer's treatment were to come to market by 2010--and if the drug delayed the onset of the disease by up to five years--the American economy could save nearly $4 trillion by 2050.

Nearly five million people in the U.S. have Alzheimer's but that number is forecast to possibly triple by mid-century.

The group that did the study gets some of its funding from Wyeth, Elan and MyriadGenetics, all of which are working on Alzheimer's treatments. Many other companies also have Alzheimer's drugs in development.

Contact U.S. News


    Get the best of CNBC in your inbox

    Please choose a subscription

    Please enter a valid email address
    To learn more about how we use your information,
    please read our Privacy Policy.

Don't Miss

U.S. Video

  • Hero miles for military members: Real estate magnate's plea

    Chairman of the Fisher House Foundation, Ken Fisher, discusses the Hero Miles program with CNBC's Dina Gusovsky. During Military Appreciation Month, Fisher is asking every traveler to donate 1,000 of their miles to replenish the Hero Miles programs that is in danger of running out.

  • Cramer shuts down this market's haters

    "Mad Money" host Jim Cramer on why this market can't stop, won't stop.

  • From the battlefield to the boardroom

    Your Grateful Nation is dedicated to helping Special Forces veterans enter the corporate world and Knot Standard provides complimentary suits to vets. Mad Money's Jim Cramer spoke with Rob Clapper, Your Grateful executive director; John Ballay, Knot Standard co-founder and president; Tej Gill, retired U.S. Navy Seal; and Darren McB, active duty U.S. Navy Seal.